161 related articles for article (PubMed ID: 29747545)
21. Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer.
Tomita M; Maeda R; Ayabe T; Nakamura K
Anticancer Res; 2020 Jul; 40(7):4023-4027. PubMed ID: 32620647
[TBL] [Abstract][Full Text] [Related]
22. Systemic immune-inflammation index is a promising noninvasive marker to predict survival of lung cancer: A meta-analysis.
Zhang Y; Chen B; Wang L; Wang R; Yang X
Medicine (Baltimore); 2019 Jan; 98(3):e13788. PubMed ID: 30653090
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of pretreatment inflammatory biomarkers in advanced lung adenocarcinoma patients receiving first-line pemetrexed/platinum doublet.
Xiong Y; Zhao N; Zheng Y; Wang J; Wei F; Ren X
Tumour Biol; 2017 Jun; 39(6):1010428317701639. PubMed ID: 28618954
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of systemic immune-inflammation index in patients with gastric cancer.
Wang K; Diao F; Ye Z; Zhang X; Zhai E; Ren H; Li T; Wu H; He Y; Cai S; Chen J
Chin J Cancer; 2017 Sep; 36(1):75. PubMed ID: 28899420
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
[TBL] [Abstract][Full Text] [Related]
26. Systemic Inflammation-Immune Status Predicts Survival in Stage III-N2 Non-Small Cell Lung Cancer.
Wang J; Hui Z; Men Y; Kang J; Sun X; Deng L; Zhai Y; Wang W; Bi N; Liang J; Lv J; Zhou Z; Feng Q; Xiao Z; Chen D; Wang L; Zhao J
Ann Thorac Surg; 2019 Dec; 108(6):1701-1709. PubMed ID: 31400325
[TBL] [Abstract][Full Text] [Related]
27. Systemic immune-inflammation index in germ-cell tumours.
Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; De Giorgi U; Mego M; Mardiak J
Br J Cancer; 2018 Mar; 118(6):831-838. PubMed ID: 29485980
[TBL] [Abstract][Full Text] [Related]
28. Elevated serum C-reactive protein, carcinoembryonic antigen and N2 disease are poor prognostic indicators in non-small cell lung cancer.
Ni XF; Wu P; Wu CP; Ji M; Wu J; Gu XF; Jiang ZX
Asia Pac J Clin Oncol; 2015 Dec; 11(4):e22-30. PubMed ID: 24889374
[TBL] [Abstract][Full Text] [Related]
29. Predictors of post-recurrence survival in patients with non-small-cell lung cancer initially completely resected.
Takahashi Y; Horio H; Hato T; Harada M; Matsutani N; Kawamura M
Interact Cardiovasc Thorac Surg; 2015 Jul; 21(1):14-20. PubMed ID: 25878187
[TBL] [Abstract][Full Text] [Related]
30. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
[TBL] [Abstract][Full Text] [Related]
31. Does advanced lung inflammation index (ALI) have prognostic significance in metastatic non-small cell lung cancer?
Ozyurek BA; Ozdemirel TS; Ozden SB; Erdoğan Y; Ozmen O; Kaplan B; Kaplan T
Clin Respir J; 2018 Jun; 12(6):2013-2019. PubMed ID: 29356383
[TBL] [Abstract][Full Text] [Related]
32. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03.
Teramukai S; Kitano T; Kishida Y; Kawahara M; Kubota K; Komuta K; Minato K; Mio T; Fujita Y; Yonei T; Nakano K; Tsuboi M; Shibata K; Furuse K; Fukushima M
Eur J Cancer; 2009 Jul; 45(11):1950-8. PubMed ID: 19231158
[TBL] [Abstract][Full Text] [Related]
33. Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection.
Diao P; Wu Y; Li J; Zhang W; Huang R; Zhou C; Wang Y; Cheng J
J Transl Med; 2018 Dec; 16(1):365. PubMed ID: 30563540
[TBL] [Abstract][Full Text] [Related]
34. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
Xu S; Cao S; Yu Y
J Cancer Res Ther; 2021 Dec; 17(7):1636-1642. PubMed ID: 35381733
[TBL] [Abstract][Full Text] [Related]
35. Pretreatment
Satoh Y; Motosugi U; Saito A; Omiya Y; Onishi H
Technol Cancer Res Treat; 2018 Jan; 17():1533033818794934. PubMed ID: 30222060
[TBL] [Abstract][Full Text] [Related]
36. The systemic immune-inflammation index is an independent predictor of survival for metastatic colorectal cancer and its association with the lymphocytic response to the tumor.
Xie QK; Chen P; Hu WM; Sun P; He WZ; Jiang C; Kong PF; Liu SS; Chen HT; Yang YZ; Wang D; Yang L; Xia LP
J Transl Med; 2018 Oct; 16(1):273. PubMed ID: 30286769
[TBL] [Abstract][Full Text] [Related]
37. Using the Systemic Immune-Inflammation Index (SII) as a Mid-Treatment Marker for Survival among Patients with Stage-III Locally Advanced Non-Small Cell Lung Cancer (NSCLC).
Biswas T; Kang KH; Gawdi R; Bajor D; Machtay M; Jindal C; Efird JT
Int J Environ Res Public Health; 2020 Oct; 17(21):. PubMed ID: 33143164
[TBL] [Abstract][Full Text] [Related]
38. Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis.
Geng Y; Shao Y; Zhu D; Zheng X; Zhou Q; Zhou W; Ni X; Wu C; Jiang J
Sci Rep; 2016 Dec; 6():39482. PubMed ID: 28000729
[TBL] [Abstract][Full Text] [Related]
39. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
40. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.
Lolli C; Basso U; Derosa L; Scarpi E; Sava T; Santoni M; Crabb SJ; Massari F; Aieta M; Conteduca V; Maruzzo M; La Russa F; Wheater M; Berardi R; Galli L; De Giorgi U
Oncotarget; 2016 Aug; 7(34):54564-54571. PubMed ID: 27409344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
